PET/X, a UW startup company, was founded with the goal to bring much needed change in how success in breast-cancer therapies is measured. Patients must currently wait and see if cancer will recur before knowing if adjuvant therapies were effective. In contrast, patient-specific evaluation of breast cancer therapy using a PET/X scanner will enable oncologists to gauge response of breast tumors to therapy within days. Notably, the PET/X scanner targets early-stage disease to allow for more options and better outcomes.